Introduction
============

Osteoporosis is the most common bone disease in the world and is characterized by low bone mass and derangement of bone microarchitecture. The prevalence of [o]{.ul}s[t]{.ul}eo [p]{.ul}orotic [f]{.ul}racture (OTPF) was estimated to be 9.0 million worldwide in the year 2000 ([@ref-20]). In a cohort of Chinese women, the prevalence rates of primary osteoporosis affecting the spine, femoral neck, and hip were reported to be 32%--34%, 16.3%, and 18.9%, respectively ([@ref-47]). In other Asian countries, the prevalence rate of osteoporosis in women ≥50 years has been reported as 34% in Korea and 31% in Japan ([@ref-8]; [@ref-18]). OTPF results in significant reductions in quality of life due to pain, depression, and disability ([@ref-36]). Elderly patients who sustain nondisplaced hip fractures experience predictable and lasting loss of function, particularly in patients with pulmonary disease. Both age and chronic obstructive pulmonary disease (COPD) affect the speed of functional recovery ([@ref-12]). Furthermore, the mortality rate following hip fracture reportedly was as high as 36% in a systemic epidemiological review ([@ref-1]). The estimated cost of treatment of osteoporosis-related fracture in the United States was approximately \$17 billion in 2005 and is estimated to increase to \$25.3 billion by 2025 ([@ref-5]).

Despite the substantial clinical burden of osteoporosis, treatment rates are low in some East Asian countries. In a national screening program in Korea, the estimated treatment rate was only 14.4% in osteoporotic women ([@ref-8]). Because low bone mineral density (BMD) is a major risk factor for fractures, timely treatment can prevent this disastrous outcome ([@ref-33]). Therefore, early identification of high-risk patients is an important step toward increasing treatment rates. However, relying on BMD screening alone is not considered sufficient to detect high-risk patients in a timely and cost-effective manner ([@ref-35]; [@ref-43]).

Patients with COPD have many shared features with osteoporotic patients, such as low body mass index (BMI), inactivity, and chronic steroid use. COPD has been shown to be associated with low BMD in recent studies ([@ref-19]; [@ref-31]). However, the association between risk of OTPF and COPD has not been well studied, particularly in the Asian population. The prevalence of osteoporosis has been shown to be higher in COPD patients compared with controls ([@ref-15]; [@ref-42]), and the prevalence of hip fracture was reportedly higher in a cross-sectional study of 465 COPD patients in Brazil ([@ref-28]). To date, no studies have been reported from East Asian countries regarding the magnitude of the risk of subsequent OTPF contributed by each clinical predictor in COPD patients. The aim of the present study was to evaluate the association between COPD and risk of OTPF and identify clinical predictors of fracture in East Asian patients. The magnitude of the risk of OTPF contributed by clinical predictors would be calculated.

Materials and Methods
=====================

Data source
-----------

Data from 2007 to 2013 was obtained from the Longitudinal Health Insurance Dataset (LHID) of the National Health Insurance Research Database (NHIRD). The National Health Insurance (NHI) program, established in 1995 in Taiwan, is a mandatory health insurance program requiring every resident, from a newborn to an elderly person, to join. It provides comprehensive insurance coverage for medical services through outpatients, inpatients, and emergency departments, in addition to traditional Chinese medicine. The program currently has a coverage rate of 99%. LHID consists of 1 million beneficiaries randomly sampled from NHIRD. The dataset includes NHI enrolment files and claims data, such as examinations, medical procedures, drug prescriptions, and diagnoses, of all included patients. The International Classification of Diseases, Ninth Revision, Clinical Modification codes (ICD-9-CM codes; 2001 revision) were used by physicians to code diseases in the system. All recognizable personal information was encrypted according to regulations specified by the Bureau of NHI. The authors have successfully conducted several population-based retrospective cohort studies using the LHID ([@ref-24]; [@ref-25]; [@ref-26]; [@ref-27]). The present study was approved by the accredited local in-house Institutional Review Board with a certificate number KTGH-IRB 10520. The IRB approved that no any form of consent (Verbal/Written) was required for this study.

Study design
------------

We conducted a population-based, observational, cohort study to assess the association between COPD and risk of OTPF. All patients diagnosed with COPD between January 2007 and December 2013 were identified (ICD-9 CM: 490--492, 496). The index date was defined as the month in which the diagnosis of COPD was made. Exclusion criteria were as follows: (1) age \<50 years; (2) less than two COPD outpatient claims within 1 year with no inpatient records; and (3) pre-existing COPD or OTPF before January 1, 2007. The control group was composed of the remaining patients in LHID without COPD, with 1 to 4 matched for age, gender, and index month, diabetes mellitus, pre-existing osteoporosis and chronic kidney disease. The exclusion criteria applied to the COPD group was used for the control group. All study patients were followed up until the first incidence of OTPF which was further separated into vertebral fractures and the other long bone fractures, drop-out from the insurance program, or the end of the present study ([Fig. 1](#fig-1){ref-type="fig"}).
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Data extraction
---------------

Patients age, gender, date of accrual, geographic residential area, insurance premium category, behavioral proxies such as smoking related diagnoses and alcohol use disorders; medical comorbidities including diabetes mellitus, pre-existing osteoporosis, chronic kidney disease, rheumatoid arthritis, hypertension, dyslipidemia, coronary heart disease, chronic liver disease, stroke and dementia; medical prescriptions such as vitamin D, inhaled corticosteroids (ICS: budesonide, beclomethasone, ciclesonide, fluticasone) and oral corticosteroids (OCS: cortisone acetate, dexamethasone, fludrocortisone, methylprednisolone, prednisolone, triamcinolone); and Charlson-Deyo Comorbidity Index Score were collected from the dataset and calculated. Longitudinal tracking data of study participants until the occurrence of a specific type of osteoporotic fracture, e.g., vertebral fracture or femoral neck fracture were extracted. Candidates who would be included were also screened for pathological fractures due to cancer metastases (ICD-9-CM code 198.5), renal osteodystrophy (588.0) and secondary hyperthyroidism (588.81).

Outcome measures
----------------

The primary outcome measure of the present study was OTPF, defined as any pathological fracture due to osteoporosis (ICD-9-CM codes: 733.0x + 733.1x) documented in inpatient or outpatient data files during the study period. Osteoporotic vertebral fracture has a unique code as 733.13. To prevent overstated or false claiming, NHI randomly and regularly reviews claims data, including patient history and laboratory and imaging reports. Only cases with correct coding for all diagnoses are eligible for full reimbursement. Any violation of the coding regulations results in payment retrieval plus a punitive fine, which may be several times the original payment. To ensure accuracy, all coding procedures were performed by groups of specialists assigned by contributing hospitals. OTPF in the present study was defined as any new and matched ICD-9 coding of cohort subjects between 2007 and 2013 in outpatient, emergent, or inpatient settings. Therefore, we believe that all events that occurred during the follow-up period were recorded with a high degree of accuracy. Furthermore, we excluded pathological fractures that resulted from cancer metastasis, renal osteodystrophy, or secondary hyperparathyroidism (ICD-9-CM codes: 733.1 + (198.5, 588.0, or 588.1)) ([Table S1](#supp-1){ref-type="supplementary-material"}). Patients with OTPF during the first follow-up year were excluded from the overall risk calculation.

Covariates and confounders
--------------------------

Socioeconomic status of participating subjects was approximated using different category by insurance premium. Exposure to different levels of sunshine was also taken into account by the use of the residential area of the participating subjects (more sunshine in the southern part of the country). Lifestyle factors included smoking-related diagnoses and alcohol used disorder were used as proxies for cigarette smoking and alcohol drinking were extracted. Medication history of inhaled corticosteroid and/or oral corticosteroid use and vitamin D prescription were extracted from the dataset. Comorbidities were identified according to ICD-9-CM codes, including rheumatoid arthritis, hypertension, dyslipidemia, coronary heart disease (CHD), liver disease, stroke, and dementia. An overall score of the Charlson-Deyo comorbidity index of each patient was collected.

Statistical analysis
--------------------

Patient-year data and incidence rates were evaluated. A multivariate Cox model was constructed to derive adjusted hazard ratios (aHR) with corresponding 95% confidence intervals (CI) after controlling for factors that were revealed significant in the univariate Cox model so that overadjustment (overfitting) and noise could be avoided. Fracture-free survival was assessed using the Kaplan--Meier analysis. Survival curves were compared between COPD and non-COPD groups using the log-rank test. Differential lag time sensitivity analysis was carried out to examine the effect of different exposure time lag on the risk of osteoporotic fractures among COPD patients who possessed the characteristic such as female and specific medical comorbidity. We used the bivariate Cox model to evaluate the risk of OTPF in COPD when coupled with each medical comorbidity. *P*-values of \<0.05 were considered statistically significant. All study analyses were performed using the SPSS statistical software (IBM SPSS Statistics Version 22).

Results
=======

Characteristics of the study population
---------------------------------------

From 2007 to 2013, 92,656 newly-diagnosed COPD patients were identified from LHID (*n* = 965,659). Among these, 70,191 were excluded after applying the exclusion criteria described above. Reasons for exclusion were as follows: incomplete data registration (*n* = 1,310) and unsuccessful matching (*n* = 5,635). As a result, 19,740 patients were recruited to the COPD sub-cohort and 78,960 to the non-COPD sub-cohort after 1 to 4 matching for age, gender, index month, diabetes mellitus, pre-existing osteoporosis and chronic kidney disease. The mean age (and standard deviation) in the COPD group was 66 years (10.23), with 62.5% of patients \<70 years of age. COPD patients were predominantly male (55.8%). The mean follow-up duration was 2.97 years (standard deviation (SD), 2.06 years) in the COPD group and 3.01 years (SD, 2.05 years) in the non-COPD group, which were not statistically significantly different (*P* = 0.0949). Hypertension and hyperlipidemia were the most commonly observed co-morbidities. Except for dyslipidemia, all non-matching co-morbidities, such as rheumatoid arthritis, hypertension, and coronary heart disease, were differently distributed between the two groups. The mean Charlson Comorbidity Index (CCI) score was significantly higher in the COPD sub-cohort (1.14 vs. 1.02; *P* \< 0.0001; [Table 1](#table-1){ref-type="table"}). More patients with COPD were classified as a regular user of oral prednisolone (16.9% vs. 6.4%; *P* \< 0.001; [Table 1](#table-1){ref-type="table"}).

10.7717/peerj.2634/table-1

###### Demographic characteristics of COPD patients and Non-COPD patients 1-to-4-matched by age, sex, index date, diabetes mellitus, pre-existing osteoporosis, and chronic kidney disease.
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  Descriptor                                                 COPD patients   Non-COPD patients   *P* value               
  ---------------------------------------------------------- --------------- ------------------- --------------- ------- ----------
  **Age mean (SD)**                                          66.02 (10.23)                       65.92 (10.23)           1
  **Age group**                                                                                                          
  50 ∼ 59                                                    6,423           32.54               26,140          33.11   
  60 ∼ 69                                                    5,915           29.96               23,501          29.76   
  70 ∼ 79                                                    5,077           25.72               20,215          25.60   
  \>80                                                       2,325           11.78               9,104           11.53   
  **Gender**                                                                                                             1
  Female                                                     8,732           44.24               34,928          44.24   
  Male                                                       11,008          55.76               44,032          55.76   
  **Other matched characteristics**                                                                                      
  Diabetes mellitus                                          4,726           23.94               18,904          23.94   1
  Osteoporosis                                               1,187           6.01                4,748           6.01    1
  Chronic kidney disease                                     2,746           13.91               10,984          13.91   1
  **Follow-up (Year)/Mean (SD)**                             2.97 (2.06)                         3.01 (2.05)             0.949
  1                                                          3,051           15.46               11,618          14.71   
  2                                                          2,976           15.08               11,707          14.83   
  3                                                          2,820           14.29               11,355          14.38   
  4                                                          2,575           13.04               10,442          13.22   
  5                                                          2,523           12.78               10,309          13.06   
  6                                                          2,597           13.16               10,754          13.62   
  7                                                          3,170           16.06               12,691          16.07   
  **Residential Area**                                                                                                   \<.0001
  North                                                      8,386           42.48               34,410          43.58   
  Central                                                    5,300           26.85               19,132          24.23   
  South                                                      5,330           27.00               22,655          28.69   
  East                                                       591             2.99                1,934           2.45    
  **Smoking-related diagnoses**                              12,353          62.58               2,772           3.51    \<0.0001
  **Alcohol use disorder**                                   598             3.03                1,557           1.97    \<0.0001
  **Insurance premium category**                                                                                         \<0.0001
  \<15,000 NTD                                               10,041          50.87               39,186          49.63   
  15,000---21,999 NTD                                        6,028           30.54               23,634          29.93   
  ≥22,000 NTD                                                3,671           18.60               16,140          20.44   
  **Comorbidities**                                                                                                      
  Rheumatoid Arthritis                                       545             2.76                1,790           2.27    \<0.0001
  Hypertension                                               11,509          58.30               44,266          56.06   \<0.0001
  Dyslipidemia                                               6,813           34.51               27,511          34.84   0.3868
  Coronary heart disease                                     5,528           28.00               17,192          21.77   \<0.0001
  Liver disease                                              3,824           19.37               13,644          19.28   \<0.0001
  Stroke                                                     3,994           20.23               12,188          15.44   \<0.0001
  Dementia                                                   1,144           5.80                2,481           3.14    \<0.0001
  **Type of ICS**                                                                                                        
  Budesonide                                                 1,214           6.17                440             0.56    \<0.0001
  Beclomethasone                                             267             1.36                169             0.21    \<0.0001
  Ciclesonide                                                46              0.23                16              0.02    \<0.0001
  Fluticasone                                                1,762           8.96                425             0.54    \<0.0001
  **Type of OCS**                                                                                                        
  Cortisone acetate                                          62              0.32                125             0.16    \<0.0001
  Dexamethasone                                              325             1.65                770             0.98    \<0.0001
  Fludrocortisone                                            18              0.09                51              0.06    \<0.0001
  Methylprednisolone                                         373             1.90                656             0.83    \<0.0001
  Prednisolone                                               3,330           16.93               5,012           6.36    \<0.0001
  Triamcinolone                                              30              0.15                97              0.12    \<0.0001
  **Vitamin D prescription**                                 487             2.48                1,689           2.14    0.0045
  **CCI score[^a^](#table-1fn1){ref-type="fn"}/Mean (SD)**   1.14 (1.36)                         1.02 (1.32)             \<0.0001
  CCI score 0                                                8,604           43.59               38,699          49.01   
  CCI score 1, 2                                             8,051           40.79               29,345          37.16   
  CCI score 3, 4                                             2,308           11.69               8,235           10.43   
  CCI score ≥ 5                                              777             3.94                2,681           3.40    

**Notes.**

COPD was excluded from the CCI score in the COPD cohort.

CCICharlson-Deyo comorbidity indexICSinhaled corticosteroidNTDNew Taiwan DollarOCSoral corticosteroidSDstandard deviation

Incidence of OTPF
-----------------

There were 131 OTPF events in the COPD group during the study period (68,743 patient-years), with an incidence rate of 1.91/1,000 patient-years. In the comparator group matched for age, gender, index month, diabetes mellitus, chronic kidney disease and pre-existing osteoporosis, there were 429 OTPF events in 278,051 patient-years, with an incidence rate of 1.54/1,000 patient-years. Patients with COPD were significantly more likely to have OTPF (crude hazard ratio (HR), 1.24; 95% CI \[1.02--1.51\]; *P* = 0.0322; [Table 2](#table-2){ref-type="table"}), as demonstrated by separation of the two cumulative incidence curves ([Fig. 2](#fig-2){ref-type="fig"}) and osteoporotic fracture-free survival curves in the Kaplan--Meier analysis ([Fig. S1](#supp-2){ref-type="supplementary-material"}).
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###### Incidence of osteoporotic fractures for COPD patients compared with non-COPD patients and crude and adjusted hazard ratio for an episode of osteoporotic fracture.
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  **Variables**                                           COPD patients   Non-COPD patients   Incidence Rate Ratio (95 % CI)   Crude HR   Adjusted HR[^a^](#table-2fn2){ref-type="fn"}                                                                              
  ------------------------------------------------------- --------------- ------------------- -------------------------------- ---------- ---------------------------------------------- ------ ----------------------- ------------------------------------------- -------------------------------------------
  **All**                                                 131             68,743.3            1.91                             429        278050.7                                       1.54   **1.24 (1.01--1.51)**   **1.24 (1.02--1.51)** (*P* = 0.0322)        1.207 (0.992--1.469) (*P* = 0.0597)
  Vertebral fractures                                     89              68743.3             1.29                             271        278050.7                                       0.97   **1.33 (1.03--1.69)**   **1.33 (1.05--1.69)** (*P* = 0.0189)        **1.297 (1.020--1.649)** (*P* = 0.0339)
  Ulna fractures                                          1               68743.3             0.01                             3          278050.7                                       0.01   1.35 (0.03--16.79)      1.35 (0.14--12.99) (*P* = 0.7943)           
  Neck of femur fractures                                 4               68743.3             0.06                             7          278050.7                                       0.03   2.31 (0.50-9.09)        2.319 (0.68--7.92) (*P* = 0.1797)           
  **Age**                                                                                                                                                                                                                                                           
  50--59                                                  10              23495.89            0.43                             22         96405.22                                       0.23   1.87 (0.79--4.10)       1                                           1
  60--69                                                  29              20797.03            1.39                             94         83199.61                                       1.13   1.23 (0.78--1.89)       **3.30 (1.61--6.77)** (*P* = 0.0011)        **2.462 (1.16--5.222)** (*P* = 0.0189)
  70--79                                                  62              17398.42            3.56                             188        69866.2                                        2.69   1.32 (0.98--1.77)       **8.44 (4.33--16.46)** (*P* \< 0.0001)      **7.124 (3.395--14.951)** (*P* \< 0.0001)
  \>80                                                    30              7051.96             4.25                             125        28579.67                                       4.37   0.97 (0.63--1.46)       **10.33 (5.05--21.13)** (*P* \< 0.0001)     **7482 (3299--16,971)** (*P* \< 0.0001)
  **Sex**                                                                                                                                                                                                                                                           
  Male                                                    23              37817.02            0.61                             57         152,742                                        0.37   1.63 (0.96--2.69)       1                                           1
  Female                                                  108             30926.28            3.49                             372        125308.8                                       2.97   1.18 (0.94--1.46)       **5.70 (3.64--8.95)** (*P* \< 0.0001)       **3.817 (2.388--6.1)** (*P* \< 0.0001)
  **Vitamin D prescription**                                                                                                                                                                                                                                        
  No                                                      108             66601.18            1.62                             380        270804.9                                       1.4    1.16 (0.92--1.43)       1                                           1
  Yes                                                     23              2142.12             10.74                            49         7245.82                                        6.76   1.59 (0.92--2.66)       **6.375 (4.06--10.00)** (*P* \< 0.0001)     **3.3 (2.08--5.236)** (*P* \< 0.0001)
  **Steroid exposure**[^b^](#table-2fn3){ref-type="fn"}                                                                                                                                                                                                             
  No steroid                                              92              41622.03            2.21                             364        219780.6                                       1.66   **1.33 (1.05−1.68)**    1                                           
  ICS regular use                                         1               2768.1              0.36                             1          688.57                                         1.45   0.25 (0.003--19.53)     0.154 (0.022--1.107) (*P* = 0.0631)         
  OCS regular use                                         1               1097.32             0.91                             1          2294.96                                        0.44   2.09 (0.03--164.17)     0.391 (0.055--2.807) (*P* = 0.3506)         
  **Smoking-related diagnoses**                                                                                                                                                                                                                                     
  No                                                      56              26518.7             2.11                             419        269633.1                                       1.55   **1.36 (1.01--1.80)**   1                                           
  Yes                                                     75              42224.6             1.78                             10         8417.64                                        1.19   1.50 (0.77--3.24)       0.848 (0.6--1.20) (*P* = 0.3497)            
  **Alcohol use disorders**                                                                                                                                                                                                                                         
  No                                                      131             67001.73            1.96                             429        273623.2                                       1.57   **1.25 (1.02--1.52)**   1                                           
  Yes                                                     0               1741.57             NA                               0          4427.45                                        NA     NA                      NA                                          
  **Insurance premium (NTD)**                                                                                                                                                                                                                                       
  \<15,000                                                64              34007.32            1.88                             257        135747.5                                       0.99   0.99 (0.74--1.31)       1                                           1
  15,000---21,999                                         60              21653.09            2.77                             158        84330.74                                       1.87   **1.48 (1.08--2.00)**   **3.56 (1.63--7.76)** (*P* = 0.0014)        1394 (0.583--3335) (*P* = 0.4554)
  ≥22, 000                                                7               13082.89            0.54                             14         57972.41                                       0.24   2.22 (0.76--5.87)       **5.18 (2.37--11.33)** (*P* \< 0.0001)      1,171 (0.472--2901) (*P* = 0.7338)
  **Geographic area**                                                                                                                                                                                                                                               
  North                                                   54              29259.38            1.85                             175        121378.3                                       1.44   1.28 (0.93--1.75)       1                                           
  Central                                                 45              18,457              2.44                             141        66933.68                                       2.11   1.16 (0.81--1.63)       1.32 (0.89--1.97) (*P* = 0.1658)            
  South                                                   29              18390.64            1.58                             101        79909.28                                       1.26   1.25 (0.80--1.91)       0.856(0.55--1.35) (*P* = 0.50)              
  East                                                    3               2130.77             1.41                             7          6843.38                                        1.02   1.38 (0.23--6.03)       0.76 (0.23--2.43) (*P* = 0.6414)            
  **Comorbidities**                                                                                                                                                                                                                                                 
  Rheumatoid arthritis                                                                                                                                                                                                                                              
  No                                                      129             67096.49            1.92                             407        272383.3                                       1.49   **1.29 (1.05--1.57)**   1                                           
  Yes                                                     2               1646.81             1.21                             22         5667.4                                         3.88   0.31 (0.04--1.27)       0.651 (0.161--2.629) (*P* = 0.5463)         
  Diabetes mellitus                                                                                                                                                                                                                                                 
  No                                                      102             53458.33            1.91                             349        216876.3                                       1.61   1.19 (0.94--1.48)       1                                           
  Yes                                                     29              15284.97            1.9                              80         61174.37                                       1.31   1.45 (0.91-2.24)        1.015 (0.672--1.533) (*P* = 0.9449)         
  Hypertension                                                                                                                                                                                                                                                      
  No                                                      52              29753.16            1.75                             149        128167.5                                       1.16   1.50 (1.07--2.07)       1                                           
  Yes                                                     79              38990.13            2.03                             280        149883.2                                       1.87   1.08 (0.83--1.40)       1.176 (0.829--1.669) (*P* = 0.3646)         
  Dyslipidemia                                                                                                                                                                                                                                                      
  No                                                      81              46397.68            1.75                             287        188947.6                                       1.52   1.15 (0.89--1.48)       1                                           
  Yes                                                     50              22345.62            2.24                             142        89103.05                                       1.59   **1.40 (1.00-1.95)**    1.305 (0.917--1.858) (*P* = 0.1386)         
  Osteoporosis                                                                                                                                                                                                                                                      
  No                                                      93              65071.05            1.43                             297        262971.8                                       1.13   1.27 (0.99--1.60)       1                                           1
  Yes                                                     38              3672.25             10.35                            132        15078.89                                       8.75   1.18 (0.80-1.71)        **7.399 (5.071--10.796)** (*P* \< 0.0001)   **301 (2.019--4487)** (*P* \< 0.0001)
  Coronary heart disease                                                                                                                                                                                                                                            
  No                                                      75              50255.5             1.49                             299        222287.6                                       1.35   1.11 (0.85--1.43)       1                                           1
  Yes                                                     56              18487.79            3.03                             130        55763.07                                       2.33   1.30 (0.93--1.79)       **2.05 (1.45--2.899)** (*P* \< 0.0001)      **1.471 (1.037--2.088)** (*P* = 0.0306)
  Chronic kidney disease                                                                                                                                                                                                                                            
  No                                                      113             60552.14            2.24                             375        245,400                                        1.83   1.22 (0.98--1.51)       1                                           
  Yes                                                     18              8191.16             2.2                              54         32650.65                                       1.65   1.33 (0.73-2.30)        1.222 (0.743--2.010) (*P* = 0.4303)         
  Liver disease                                                                                                                                                                                                                                                     
  No                                                      109             56439.49            1.93                             352        235095.9                                       1.5    **1.29 (1.03--1.60)**   1                                           
  Yes                                                     22              12303.81            1.79                             77         42954.81                                       1.79   1.0 (0.59--1.62)        0.944 (0.597--1.493) (*P* = 0.8051)         
  Stroke                                                                                                                                                                                                                                                            
  No                                                      111             56270.64            1.97                             343        238988.5                                       1.44   **1.37 (1.10--1.71)**   1                                           
  Yes                                                     20              12472.65            1.6                              86         39062.17                                       2.2    0.73 (0.42--1.20)       0.834 (0.518--1.344) (*P* = 0.456)          
  Dementia                                                                                                                                                                                                                                                          
  No                                                      125             65485.98            1.91                             408        270683.4                                       1.51   **1.26 (1.03--1.55)**   1                                           
  Yes                                                     6               3257.32             1.84                             21         7367.3                                         2.85   0.65 (0.21--1.66)       1.003 (0.442--2.277) (*P* = 0.9934)         

**Notes.**

Hazard ratio calculation: For fracture sites, comparison was made between COPD and non-COPD; in subcategories such as age and sex, HR is based on the comparison among subcategories with the reference group.

Multivariate Cox regression model derived HR was adjusted for sex, age group, vitamin D prescription, insurance premium category, pre-existing osteoporosis and coronary heart disease.

Only regular users by pre-determined definitions were included for analysis.

EventNumber of Osteoporotic FracturesPYPerson YearsRateIncidence per 1,000 PYCKDChronic kidney diseaseHRHazard RatioICSinhaled corticosteroidsIHDIschemic heart diseaseNAnot applicableOCSoral corticosteroids

Bold type numerals denote statistical significance.

After multivariate Cox proportional hazards regression controlling for sex, age, vitamin D prescription, insurance premium category, pre-existing osteoporosis and coronary heart disease, the difference between the two groups lost statistical significance (aHR, 1.21; 95% CI \[0.992--1.469\]; *P* = 0.0597). However, when the outcome was a vertebral OTPF, both crude HR (1.33; 95% CI \[1.05--1.69\]; *P* = 0.0189) and aHR (1.297; 95% CI \[1.020--1.649\]; *P* = 0.00339) were statistically significant. [Fig. 3](#fig-3){ref-type="fig"} demonstrates the clear separation of the two cumulative incidence curves. Owing to few events as long bone fracture, the crude HRs were non-significantly increased, for example, in ulnar fractures and femoral neck fracture ([Table 2](#table-2){ref-type="table"}).

![Cumulative incidence curves of osteoporotic fracture in COPD patients and non-COPD comparators matched for age, sex, index date, osteoporosis, diabetes mellitus and chronic kidney disease.](peerj-04-2634-g002){#fig-2}

![Cumulative incidence curves of osteoporotic vertebral fracture in COPD patients and non-COPD comparators after multivariate adjustment.](peerj-04-2634-g003){#fig-3}

It is noteworthy that COPD patients who were older (up to 7.5-fold increase of the risk in terms of aHR in patients aged \>80 years as compared with the age group of 50--59 years), female (3.8-fold increase), who received vitamin D prescriptions (3.3-fold increase), with pre-existing osteoporosis (3-fold increase) or with coronary heart disease (1.5-fold increase) had higher risk for OTPF than their non-COPD comparators ([Table 2](#table-2){ref-type="table"}). In sensitivity analysis based on differential lag time with vertebral OTPF as the outcome, female COPD patients had a sustained and progressively increased risk of vertebral OTPF compared with non-COPD females from the second (aHR = 3.3; 95% CI \[1.89--5.74\]; *P* \< 0.0001) to fifth (aHR = 8.0; 95% CI \[1.81--35.4\]; *P* \< 0.01) follow-up year. In COPD patients with pre-existing osteoporosis, the risk of vertebral OTPF, approximately 3- to 4-fold increased, sustained through to the fifth follow-up year. COPD patients who were co-prescribed vitamin D had an statistically significantly increased risk in the second (aHR = 3.62; 95% CI \[2.1--6.23\]; *P* \< 0.0001) and third (aHR = 2.97; 95% CI \[1.48--5.97\]; *P* \< 0.01) follow-up year ([Table 3](#table-3){ref-type="table"}). Comorbidities, such as rheumatoid arthritis, diabetes mellitus, hypertension, dyslipidemia, CKD, liver disease, stroke, or dementia, were not associated with OTPF. In addition, steroid exposure, smoking related diagnoses, alcohol use disorders, and geographic region, were not associated with OTPF ([Table 2](#table-2){ref-type="table"}).

Discussion
==========

We believe this to be the first longitudinal cohort study with a meticulous study design to examine the relationship between COPD and risk of OTPF, particularly vertebral fracture, in an East Asian population. Compared with the comparison cohort matched for age, gender, index month, pre-existing osteoporosis, diabetes mellitus and chronic kidney disease, Asian COPD patients had a significantly increased risk of developing OTPF, with a crude HR of 1.24 (95% CI \[1.02--1.51\]). When we examine the OTPF by site, the risk for vertebral fractures in COPD patients increases by approximately 30% even after statistical adjustment for confounding factors. In addition to pre-existing osteoporosis, female gender and those who require vitamin D prescription were important clinical predictors of vertebral OTPF in the COPD population.

Chen and colleagues ([@ref-7]) published a retrospective cohort study to examine the risk for osteoporosis in COPD patients in the same region as ours. Nevertheless, the study reveals some shortcomings: first, pathological fractures resulted from bone metastases, renal osteodystrophy and hyperparathyroidism were not excluded; second, comparators were not matched for pre-existing osteoporosis, diabetes mellitus, and chronic kidney disease; third, vitamin D prescription was not taken into account; and lastly, a half of the COPD cohort aged below 50 years, which are not an optimal population to examine osteoporosis for. Another population-based retrospective cohort study to examine the association between COPD and hip fracture ([@ref-17]) revealed that patients with COPD had an approximately 60% greater risk of sustaining hip fracture. Our study cannot confirm this association (crude HR = 2.319; 95% CI \[0.68--7.92\]; *P* = 0.1797). Further studies are needed to confirm the potentially existing risk.
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###### Sensitivity analysis showing the effect of differential time lag on the risk of osteoporotic vertebral fractures among COPD patients who possessed the contributing characteristics.

![](peerj-04-2634-g006)

  Predictive variable      2nd follow up year   3rd follow up year   4th follow up year                                              5th follow up year   6th follow up year   7th follow up year                                                                                                                                                                                                                                                                                     
  ------------------------ -------------------- -------------------- --------------------------------------------------------------- -------------------- -------------------- --------------------------------------------------------------- -------------- ------- ------------------------------------------------------------ -------------- ------- ------------------------------------------------------------ -------------- ----- -------------------- -------------- ----- ---------------------
  Female                   7,439/ 9,222         72/ 17               **3.3 (1.89--5.74)**[^\*\*\*\*^](#table-3fn5){ref-type="fn"}    6,177/ 7,508         48/11                **3.48 (1.75--6.9)**[^\*\*\*^](#table-3fn4){ref-type="fn"}      4,909/ 5,956   31/6    **4.46 (1.81--11.03)**[^\*\*^](#table-3fn3){ref-type="fn"}   3,762/ 4,528   20/2    **8.0 (1.81--35.4)**[^\*\*^](#table-3fn3){ref-type="fn"}     2,623/ 3,144   8/0   --                   1,444/ 1,726   2/0   
  Osteoporosis             959/ 15,702          27/62                **3.31 (2.04--5.35)**[^\*\*\*\*^](#table-3fn5){ref-type="fn"}   758/ 12,927          17/42                **3.35 (1.84--6.09)**[^\*\*\*\*^](#table-3fn5){ref-type="fn"}   568/ 10,297    10/27   **3.51 (1.64--7.51)**[^\*\*^](#table-3fn3){ref-type="fn"}    393/ 7,897     7/ 15   **4.08 (1.61--10.35)**[^\*\*^](#table-3fn3){ref-type="fn"}   253/ 5,514     2/6   2.45 (0.48--12.41)   125/ 3,045     1/1   595 (0.3--117.73)
  Vitamin D Prescription   468/ 16,193          17/ 72               **3.62 (2.1--6.23)**[^\*\*\*\*^](#table-3fn5){ref-type="fn"}    419/ 13,266          10/ 49               **2.97 (1.48--5.97)**[^\*\*^](#table-3fn3){ref-type="fn"}       360/ 10,505    4/33    1.69 (0.59--4.87)                                            295/ 7,995     3/ 19   1.9 (0.55--6.57)                                             212/ 5,555     2/6   4.48 (0.88--22.9)    116/ 3,054     1/1   8.87 (0.46--170.54)
  Coronary Heart Disease   4,590/ 1,2071        38/51                1.45 (0.95--2.22)                                               3,724/ 9,961         24/35                1.39 (0.82--2.34)                                               2,913/ 7,952   12/25   1.04 (0.52--2.09)                                            2,148/ 6,142   7/15    0.97 (0.39--2.41)                                            1,437/ 4,330   2/6   0.69 (0.14--3.47)    764/ 2,406     0/2   

**Notes.**

Bold type numerals denote achieving statistically significant.

*P* \< 0.05.

*P* \< 0.01.

*P* \< 0.001.

*P* \< 0.0001.

x/y: number of patients at risk with the characteristic/number of patients at risk without the characteristic.

A/B: number of patients who developed osteoporotic fracture in X/number of patients who developed osteoporotic fracture in Y.

The Cox model was adjusted for sex, age group, vitamin D prescription, and pre-existing osteoporosis.

The prevalence of osteoporosis was significantly higher in COPD patients compared with healthy subjects, with prevalence rates of 9%--69% in COPD patients ([@ref-15]). The association between COPD and osteoporosis has been reported in many studies. In a very elderly Chinese male population, COPD was found to be independently associated with low femoral neck bone mineral density ([@ref-3]). Higher Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage is reportedly correlated with lower bone mineral density, with every unit decrease in respiratory function (expressed as FEV1 in L/s) associated with a decrease in BMD of approximately 0.02 g/cm^2^ ([@ref-29]; [@ref-30]; [@ref-45]). This association was independent of potential confounding factors, such as age, smoking habit, major comorbidity, and medications.

However, only a few studies have examined whether patients with COPD have a higher risk of developing OTPF. A recent small cross-sectional study reported by Watanabe and colleagues reveals that the prevalent vertebral fracture is as high as 79.4% in Japanese men with COPD ([@ref-46]). A case-control study demonstrated an independent association between COPD and increased risk of hip fracture in Catalonians ([@ref-39]). In a multicenter cross-sectional study, Diez-Manglano and colleagues observed a high probability of fracture in 347 Spanish COPD inpatients. Overall, nearly half of the COPD patients (95% CI \[44.8--54.7\]) had a probability of hip fracture in the next 10 years. The probability of fracture was not related to the GOLD stage. An American retrospective observational study of 87,360 COPD veterans reported a high incidence rate of hip fractures during four years of follow-up, with 3.99 events/1,000 person-years ([@ref-32]). However, this study did not include a comparative cohort for the study population. None of the studies mentioned above used a prospective design method. In a further study with a 6-year follow-up of 5,541 males in the general population, patients with COPD or asthma had lower BMD than patients without COPD or asthma, with adjusted odds ratio for vertebral and non-vertebral fractures of 2.6 and 1.4, respectively (odds ratio for presence of COPD or asthma vs. absence of COPD or asthma, 2.64; 95% CI \[1.57--4.44\]; and 1.42; 95% CI \[1.03--1.96\], respectively) ([@ref-10]). However, the inclusion of patients with asthma limited the ability to evaluate the contribution of COPD to fracture outcomes. Because the abovementioned studies were conducted in the western population and three included men only ([@ref-10]; [@ref-32]; [@ref-39]), the generalizability to populations in Eastern countries is questionable.

The association between COPD and OTPF observed in the present study may be attributable to shared risks between both conditions, such as smoking, physical inactivity, low body weight, and malnutrition ([@ref-4]; [@ref-10]; [@ref-21]). Moreover, serum vitamin D levels may also contribute to the risk of OTPF. It has been shown that decreased vitamin D levels were independently associated with increased risk of osteoporosis (defined as vertebral fracture without decreased BMD) by 7.5-fold ([@ref-14]).

It should be noted that OTPF may result from events other than osteoporosis, such as falls. COPD patients typically have many shared risk factors for falls, such as muscle weakness, mobility impairment, and exercise intolerance ([@ref-22]; [@ref-40]). Compared with healthy controls, the presence of COPD has been shown to be associated with significantly impaired ability to perform balance tests, such as the Berg Balance Scale, timed up and go test, and single-leg stance ([@ref-9]; [@ref-37]). An observational cohort study reported a high prevalence of previous falls in COPD patients (32%), with an incidence rate of 0.1 (95% CI \[0.06--0.14\]) falls/person-month ([@ref-41]). In a population-based study, Sibley et al. reported that COPD was significantly associated with increased risk of falls ([@ref-44]). Thus, in addition to osteoporosis, risk factors for falls may play an important role in the correlation between COPD and OTPF. The treatment of such risk factors and osteoporosis is likely required for successful fracture prevention.

Patients with CKD are at an increased risk of fragility fracture ([@ref-34]), which may be explained by CKD-related bone mineral disease and high coprevalence of CKD and osteoporosis in elderly individuals ([@ref-23]). This is the reason why our study design employed matching the comparison group by this factor.

The present study had some clinical implications. According to current guidelines, osteoporosis screening is not recommended for patients with COPD. In the present study, we identified COPD as a potential risk factor for OTPF, particularly vertebral OTPF and the contributing predictors of vertebral OTPF are female COPD patients or those with pre-existing osteoporosis or required vitamin D prescription. Timely arrangement of BMD scanning may increase the possibility of treating osteoporosis and reduce the risk of fracture in this high-risk population. Systemic corticosteroid should be used with cautious as the incidence of fracture increases with duration and dosage of steroid therapy ([@ref-6]; [@ref-38]). Because 87%--90% of elderly fractures result from falls ([@ref-11]; [@ref-13]), strategies to prevent falls should be implemented in at-risk patients, such as medication review, environmental adjustment, and exercise training. Previous studies have shown that balance training in COPD patients has utility in improving important fall-related factors, such as function, muscle strength, and balance performance ([@ref-2]; [@ref-16]). Thus, introducing balance training component into currently existing exercise programs for COPD patients may be of more value in OTPF prevention.

Several limitations of the present study have to be acknowledged. First, we were unable to obtain data regarding important fracture risk factors, including BMI, bone marrow density, and calcium intake, family history of OTPF, and physical activity level. Second, the propensity for falls could not be determined because data for risk factors, such as gait abnormality, visual impairment, and living environment, were unavailable. Third, COPD diagnoses were obtained from a claimed dataset, which might not be as accurate as diagnoses made by standardized protocols or tools. However, we excluded outpatients claiming less than two times per year without an inpatient record to increase accuracy. Lastly, the true incidence of prevalent fracture which is existent morphological fracture identified by x-ray during the study period cannot be determined. In the current study, the authors only picked up "clinical fractures" with symptoms because most patients were not taking screening spinal x-ray exams. Thus, upon subject recruitment, a prevalent asymptomatic vertebral fracture can potentially be missed. Similarly, the fracture that this research was looking at was physician-diagnosed clinical fracture identifiable in the national claims database. Thus, the true vertebral fracture incidence during the study period is unknown. Thanks to the nationwide frailty intervention health programs established in Taiwan aiming to reduce the risk of falls and fractures, many if not all asymptomatic pre-clinical vertebral OTPFs have already been screen-detected. The risk of misclassification bias is thus much reduced.

The study has several strengths. First, we used compulsory administrative data to identify our study cohorts, which avoids possible volunteer or selection bias. Second, patients in the COPD group of the present study were meticulously matched with individuals without COPD, thereby minimizing possible confounding or bias that may affect other observational studies. Third, the sample of the present study was large and nationwide, increasing the generalizability of the present findings. We believe the effect of the large sample size of the present study may overcome some of the confounding factors caused by minor issues, such as code misclassification and minor differences between the two cohorts or use of medications that effect bone metabolism. Fourth, we excluded patients with fractures that occurred within the first year of COPD diagnosis, which may have been caused by other factors as the time was too short for COPD to have affected bone metabolism.

In conclusion, the present large-scale longitudinal study conducted in the Asia-pacific region found an association between OTPF in COPD patients. Among patients with COPD, the risk of fractures was significantly increased in female patients, and those with a diagnosis of osteoporosis, or those who require vitamin D prescription indicating risk for osteoporosis. These results indicate the importance of fall prevention and osteoporosis treatment in patients with COPD. Further prospective cohort studies are required to confirm the causal relationship between COPD and OTPF.
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